We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings

39 hedge funds and large institutions have $41.7M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

22% more funds holding

Funds holding: 32 → 39 (+7)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

70% less capital invested

Capital invested by funds: $137M → $41.7M (-$95.1M)

Holders
39
Holders Change
+7
Holders Change %
+21.88%
% of All Funds
0.61%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
12
Increased
7
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$2.41M
2
WSL
Western Standard LLC
California
+$1.1M
3
NM
Newtyn Management
New York
+$848K
4
AI
Acuitas Investments
Washington
+$689K
5
VAM
Vazirani Asset Management
New York
+$327K

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$3.21M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.98M
3
NHAS
Novo Holdings A/S
Denmark
-$582K
4
Morgan Stanley
Morgan Stanley
New York
-$250K
5
CCM
CAAS Capital Management
New York
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$9.52M -$582K -277,777 -7%
BCM
2
BML Capital Management
Indiana
$8.45M +$217K +103,704 +3%
OMC
3
OUP Management Company
Pennsylvania
$6.39M – – –
NM
4
Newtyn Management
New York
$3.53M +$848K +405,102 +43%
AFM
5
Anson Funds Management
Texas
$2.99M +$2.41M +1,151,662 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$2.15M -$2.98M -1,424,464 -63%
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.52M – – –
WSL
8
Western Standard LLC
California
$1.36M +$1.1M +524,050 New
LCM
9
Laurion Capital Management
New York
$935K – – –
AI
10
Acuitas Investments
Washington
$856K +$689K +329,173 New
VAM
11
Vazirani Asset Management
New York
$406K +$327K +156,135 New
EWM
12
Evercore Wealth Management
New York
$381K – – –
AC
13
Aldebaran Capital
Indiana
$374K -$15.7K -7,500 -5%
Renaissance Technologies
14
Renaissance Technologies
New York
$363K -$75.9K -36,234 -21%
CF
15
Cantor Fitzgerald
New York
$343K +$277K +132,096 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$309K – – –
RC
17
RBF Capital
California
$305K – – –
BlackRock
18
BlackRock
New York
$230K +$15K +7,161 +9%
Bank of America
19
Bank of America
North Carolina
$209K +$27.1K +12,935 +19%
MAM
20
Marquette Asset Management
Minnesota
$177K – – –
CL
21
CSS LLC
Illinois
$157K +$127K +60,454 New
PFCS
22
Pale Fire Capital SE
Czech Republic
$150K +$121K +57,597 New
CCM
23
CAAS Capital Management
New York
$89.8K -$243K -115,870 -77%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$67.3K -$209 -100 -0.4%
State Street
25
State Street
Massachusetts
$62K – – –
1
2

CYT Hedge Fund Activity: Q2 2023 in Review

39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q2 2023, worth a combined $41.7M — down 70% from $137M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CYT positions and 5 closed out — a net gain of 7 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.41M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.21M sold.

  • 39 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q2 2023, up from 32 in Q1 2023.
  • Funds reported $41.7M of Cyteir Therapeutics, Inc. Common Stock stock for Q2 2023, down 70% quarter-over-quarter.
  • 12 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q2 2023 and 5 closed out, a net change of +7 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q2 2023 was Anson Funds Management, an estimated $2.41M added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q2 2023 was Avidity Partners Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2023.